high risk consensu estim solosec
levothyroxin
cut ep consensu take
deep dive prospect solosec levothyroxin levo proair
lupin account ep growth see high risk
consensu ep estim solosec levo half consensu
slower ramp-up lower peak sale solosec levo proair
expect solosec peak sale mn vs consensu mn
solosec tier formulari access step therapi patient tri
altern first even co-pay coupon net cost patient
solosec vs co-pay metronidazol tablet show case studi
absorica tier access volum share cap despit
aggress co-pay slow start far share three month
guidanc vs absorica reach share first year
expect levo sale mn vs consensu mn given
market size smaller mn brand volum convert gener
price vs consensu work bn ramp-up slow
patient typic switch requir thyroid-level retest post switch given
levo narrow therapeut drug lupin need approv four
brand expect proair teva could aggress defend
share proair top three drug teva teva aggress protect share
copaxon azilect proair could mn peak lupin
resolut warn letter goa indor plant key event
alreadi price alreadi assum resolut
estim includ sharp increas approv two plant
valuat expens ep three drug
ep cut ep factor lower solosec
levo risk cut boost near-term profit impact growth
valuat metric
chg prev ep
number share mn
price month
price rel chart measur perform
 bse sensex close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
figur levo peak lupin
gener
focu chart tabl
figur solosec turn ebitda posit
ep posit
figur solosec tier access step
therapi instanc formulari condit
failur metronidazol
treatment failur ith atleast one
failur atleast one
cover solosec
figur solosec price high vs bv drug
figur volum gener
thu slower ramp-up new player
figur proairteva retain high share
key product defend volum proair
lupin limit india-bas pharmaceut compani
compani develop market rang gener formul
activ pharmaceut ingredi api market around
world focus chronic therapi lifestyl segment
good sold
profit tax
free cash flow firm
net chang cash
price eros us remain mid-singl digit lupin
multipl revert histor average
delay resolut warn letter goa indor plant price
eros us goe doubl digit lupin see
earn cut de-rat
price rel chart measur perform bse sensex
close
spot exchang rate
strategi
aggress lupin
max volum share
switch levo
slow patient need
retest thyroid-
level post switch
thu ramp-up slower
pro-air top three
drug teva
like teva defend
aggress
copaxon azilect
consensu estim
solosec levothyroxin
solosec peak sale half market expect
solosec indic bacteri vaginosi bv key advantag higher complianc
one-dosag treatment vs day treatment exist drug metronidazol
clindamycin market overestim peak sale solosec mn
solosec tier formulari access step therapi patient tri altern
treatment first prior authoris even steep co-pay coupon net cost
patient solosec vs metronidazol tablet co-pay
present case studi absorica also tier access even aggress
coupon strategi co-pay patient reduc tier co-pay market share
cap absorica price gener slow start solosec
volum share first three month guidanc reach share exit
share three four year compar absorica reach volum
share first year overal expect solosec peak lupin
mn solosec turn ebitda posit ep accret
levothyroxin sale half consensu
given lower market size slower ramp-up
consensu expect levo sale mn lupin lower
mn given market size levo smaller consensu believescurr
gener market mn gener control prescript gener
price overal market mn vs market work bn ramp-
lupin post approv slow first lupin need approv
four brand levo happen second levo
narrow therapeut drug exist patient switch prescript often thu
ramp-up slower convent gener patient typic advis
thyroid level retest potenti dose readjust levo prepar
switch pharmaci current levo four player market one brand synthroid
three gener competit turn seven player lupin take
two year reach market share levo peak sale mn
thereaft sale declin market becom competit
teva copaxon gener
pro-air good limit competit opportun lupin howev chanc high
teva aggress defend market share pro-air among top three drug
teva teva alreadi retain high market share copaxon azilect
market size similar pro-air proair market mn manufactur level
like teva retain volum share therefor lupin may get
share depend get approv first among lupin current
complet respons letter initi guid quarter launch
ep guidanc mn pat mn suggest impli market
share overal proair could mn mn depend whether
lupin get share
overal cut ep factor slower ramp-up solosec
levothyroxin target price base ep base histor
multipl risk sharp cut boost near-term profit impact longer-
charl martineau pm univers toronto lupin guid
market share
solosec year
reach share
major bv
market
metronidazol
treatment price
price high
solosec peak sale half market
solosec indic bacteri vaginosi bv key advantag solosec higher
complianc one-dosag treatment vs day treatment exist drug
metronidazol clindamycin view market overestim peak sale
solosec mn solosec tier access formulari step
therapi requir patient tri altern treatment first prior authoris
even steep co-pay coupon lupin net cost patient solosec
compar metronidazol tablet co-pay present case studi
absorica tier access like solosec even aggress coupon strategi
co-pay patient reduc tier co-pay market share cap absorica
price gener slow start solosec captur volum
share first three month lupin guid reach share exit
share three four year compar absorica reach volum share
first year overal expect solosec peak lupin mn solosec
turn ebitda posit ep accret
solosec price significantli higher compar
solosec indic bacteri vaginosi solosec ten-year exclus nce
exclus five year qidp design provid exclus anoth five year
patent lupin start market exclus start sep-
key advantag solosec higher complianc one-dosag treatment
vs day treatment exist drug metronidazol tinidazol howev solosec
price significantli higher treatment option bv commonli
use oral treatment bv metronidazol price seven-day treatment
wherea even discount solosec cost patient uninsur
center diseas control prevent cdc recommend treatment bv
figur bacteri vaginosi treatment option treatment cost
 daili day
 daili day
price goodrx compani data credit suiss estim
solosec market share limit formulari
access step therapi
lupin achiev insur access solosec insur
plan solosec approv step therapi requir patient tri
altern treatment first solosec reimburs insur compani
altern treatment bacteri vaginosi metronidazol tab
tinidazol tab metronidazol vagin gel clindamycin capsul cream
charl martineau pm univers toronto insur programm requir patient use least one drug
solosec cover insur compani list figur condit set
formulari solosec coverag
figur instanc solosec coverag condit formulari
cross shield kansa citi
condit coverag solosec
failur metronidazol clindamycin least one
treatment failur least one metronidazol tab tinidazol
failur least oneclindamycin capsules/cream metronidazol tab
cover solosec
tier step therapi limit quantityonc day
tier access prior authoris step therapi
tier access prior authoris requir prescript fill
cross shield arizona
cover solosec
reid hospit health servic formulari cover solosec
tier access equival tier access other
tier access equival tier access other
co-pay tier access
typic high
patient co-pay
vs lupin co-pay
reduc
lupin gone tier access insur compani make solosec
non-pref brand choic limit lupin gener alreadi
avail present tier lupin could tri tier list would
requir lupin share higher rebat insur compani although co-pay
patient would lower case instead lupin opt tier access
also provid co-pay coupon patient reduc co-pay option better
lupin prefer brand tier case take approach
lupin save rebat insur compani
figur formulari tier associ co-pay
drug cover tier
studi absorica tier access coupon
provid case studi absorica view similar case solosec
absorica oral isotretinoin use clear sever acn reduc risk
relaps absorica brand drug multipl gener version isotretinoin
also avail differ gener product taken fatti meal
ensur adequ absorpt howev absorica formul allow absorpt
regardless meal term efficaci safeti signific differ
absorica gener therefor given high price absorica
gener list tier drug formulari requir prior
authoris step therapi cover absorica insur
charl martineau pm univers toronto list price solosec
net price
prescript lupin
mn peak
sale base
given tier access absorica sun pharma follow aggress coupon
strategi lower patient co-pay low vs without coupon
similar co-pay put context lupin co-pay coupon reduc
patient co-pay typic tier co-pay coupon
lupin list price solosec per packet tier rebat pbm effect
price adjust coupon net price lower especi
initi stage launch coupon appli privat insur
appli state feder fund programm therefor coupon appli
solosec prescript even take conserv number half
patient use co-pay coupon net realis lupin
initi stage
also look absorica posit tier co-pay strategi help term
market share absorica achiev averag market share mostli despit
support aggress co-pay coupon lower market share absorica
explain step therapi prior authoris requir formulari coverag
interest note case absorica initi ramp-up period one
year achiev market share wherea lupin guid achiev market
share solosec
figur absorica volum market share remain
market overestim peak sale solosec
market size bacteri vaginosi mn prescript last month data
almost prescript roughli vagin cream gel therefor
address market solosec mn prescript appli learn
absorica case studi also fact insur programm put
step therapi solosec requir prior approv expect peak market share
solosec vs manag guid market share net realis
market share oral categori peak sale lupin
come mn high end lupin guidanc share solosec
could peak mn sale
consensu expect higher product expect solosec
like reach cross mn sale well requir lupin get
market share could high task given formulari posit step therapi
use alreadi genericis metronidazol tab metronidazol vagin gel
clindamycin cream tinidazol tab
charl martineau pm univers toronto figur tablet form bv market
figur prescrib base equal split
nurs practition obstetrics/gynaecologist
solosec ramp-up
slow far
share first three
key question fast lupin ramp market share first year absorica
achiev peak market share end first year launch co-pay
coupon absorica much aggress co-pay effect
reduc tier co-pay gener drug case solosec co-pay
coupon reduc still higher compar total cost
treatment metronidazol tablet seven day recent
confer call lupin manag also guid lupin expect hit market share
solosec end hit market share three four year
figur lupin achiev volum share
oral bv market three month far
figur solosec turn ebitda posit
ep posit
lupin share royalti
solosec also
lupin share royalti solosec well
ebitda margin
lupin mention time solosec acquisit addit mn
acquisit consider lupin also pay royalti solosec lupin quantifi
royalti mention royalti pay solosec lower usual deal
rang mid-teen industri assum royalti paid lupin
solosec lupin total field forc rep rep primari physician
rep focus ob-gyn
overal expect solosec turn ebitda posit ep accret
ebitda margin solosec peak sale howev
manag target mn sale achiev peak ebitda margin
well
levothyroxin sale half
consensu expect given lower size
slower ramp-up
consensu work levothyroxin sale mn lupin
view realist sale mn given market size levo smaller
consensu believesth current gener market mn gener control
prescript gener price overal market mn vs market work
bn ramp-up lupin post approv slow first lupin
need approv four brand levo happen vs
approv synthroid second levo narrow therapeut drug
exist patient switch prescript often thu ramp-up slower
convent gener physician typic advis patient thyroid level
retest potenti dose readjust everi time levo prepar
switch pharmaci
current levo four player market one brand synthroid three gener
lannett sandoz competit turn seven player market expect
lupin take two year reach market share levo peak sale mn
thereaft sale start declin market becom competit
relev levothyroxin market lupin smaller
consensu take
levothyroxin market bn market size manufactur level
howev half market valu synthroid effect price
gener therefor total levothyroxin market price gener
mn relev market size lupin perspect
levo
prescript
alreadi gener
synthroid price
gener
figur levo bn market
half market brand synthroid
figur net price synthroid
valu split levo
volum split levo
four refer list drug rld levothyroxin name synthroid unithroid
levoxyl levothroid three gener present market lannett
sandoz practic purpos levo current four-play market brand sale
unithroid levoxyl low unithroid lannett gener distribut right
start amneal start distribut gener unithroid gener
steadili gain market share levothyroxin market account
volum share compar domin market share
follow lannett synthroid sandoz
figur levothyroxin current effect four player market one brand
synthroid three gener
lupin ramp-up synthroid slower
ramp-up slow due two reason lupin initi approv
synthroid rld take anoth six month get approv three rld
qualifi substitut major market patient switch
two differ brand gener low levothyroxin switch requir
patient undergo repeat thyroid function test check dose retitr therefor
even possibl get levo approv lupin may take anoth year take
meaning market share howev market alreadi work levo sale
mn lupin
synthroid sticki prescript
initi ramp-up synthroid rld slow given sticki synthroid
prescript despit three gener market synthroid still get
new brand prescript retain current prescript share
due fact levothyroxin narrow therapeut index drug therefor
patient comfort brand drug levothyroxin
expens product absolut basi effect price brand
new
still go synthroid
despit presenc
charl martineau pm univers toronto figur gener market share levothyroxin
figur synthroid new brand share
stay despit three
gener market share levothyroxin
synthroid new brand volum share
figur wac price strength levothyroxin tablet
price levothyroxin
patient advis
switch
levo made
exist patient switch prescript often thu ramp-up
slower convent gener
bioequival studi gener levo allow confid interv
accept criterion accept interv result variat
differ drug given levo narrow therapeut index drug rang
serum levothyroxin therapeut toxic concentr narrow
signific clinic consequ excess inadequ treatment patient switch
differ levothyroxin drug may respond differ reason patient
advis repeat thyroid function test allow dose retitr want
highlight differ strength levothyroxin close place mcg
charl martineau pm univers toronto competit
sharpli increas
levo three
gener current
six
therefor switch exist market share slow patient receiv new
levothyroxin prepar need retest serum tsh determin need
dose retitr therefor physician typic encourag patient ask remain
prepar everi pharmaci refil make sure patient understand
need tsh retest potenti dose readjust everi time
levo prepar switch
levothyroxin turn seven player market
recent confer call lupin guid could addit two gener
addit lupin get approv turn levo market
four player market seven player market levothyroxin guidanc updat
fda dmf file includ gland pharma july-
lupin apotex macleod jan
dr reddi litig levothyroxin inject form
possibl could pursu tablet form well therefor competit
enter levothyroxin market
expect lupin sale levothyroxin mn six
gener peak mn seven gener thereaft levo
sale lupin start declin
figur levothyroxin peak mn sale lupin
gener
charl martineau pm univers toronto pro-air top three
drug teva
like teva defend
aggress
copaxon azilect
expect lupin get
thu pro-air
opportun lupin
teva copaxon
pro-air good limit competit opportun lupin market like
three gener player market includ authoris gener two three year
howev problem lupin perspect pro-air among top three brand
drug teva possibl high teva may respond aggress protect
market share teva alreadi done larg brand drug like
copaxon azilect azilect similar size proair far teva retain
volum share copaxon despit presenc two gener teva market
share azilect despit three gener well
proair market mn manufactur level vs im show high
bn like teva retain volum share therefor lupin may get
share depend get approv first among lupin
current complet respons letter initi guid quarter
launch ep guidanc mn pat mn suggest impli
market share overal proair could mn opportun depend
whether lupin get share
pro-air among top three brand drug teva
pro-air among top three drug teva expect aggress respons
teva protect market share teva copaxon azilect azilect drug
size similar proair
figur proair inhal teva mn
drug among top three brand drug
figur sale im level significantli higher
manufactur level albuterol inhal
teva retain major market copaxon
teva far retain volum share copaxon despit presenc two
gener teva market share azilect despit three gener
well expect teva retain volum share proair well
therefor lupin may get share depend get approv first among
lupin current complet respons letter
charl martineau pm univers toronto figur teva retain larg volum share
copaxon
figur also azilect lead
drug teva mn sizeteva
share four gener market
guidanc impli market share proair
earlier guid quarter launch proair gener also guid
addit ep equival mn per quarter net profit
later withdrew guidanc receiv complet respons letter proair
therefor abl launch quarter howev work
impli market share could give pat mn per quarter work
market share assum approv gener
togeth teva authoris gener valid
easi get signific market share away teva key brand product
cut ep target price
overal cut ep factor slower ramp-up solosec
levothyroxin target price base ep risk sharp
cut boost near-term profit impact long-term growth
compani mention price
